HUE051357T2 - IL-23 kötõ antitestek - Google Patents

IL-23 kötõ antitestek

Info

Publication number: HUE051357T2
Authority: HU; Hungary
Prior art keywords: binding antibodies; antibodies; binding
Prior art date: 2013-03-08

Application number

HUE14761062A

Other languages

English (en)

Inventor

Catherine Brautigam Beidler

Stuart Willis Bright

Daniel Scott Girard

Kristine Kay Kikly

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-08

Filing date

2014-03-04

Publication date

2021-03-01

2014-03-04 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2021-03-01 Publication of HUE051357T2 publication Critical patent/HUE051357T2/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Diabetes (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Transplantation (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

HUE14761062A 2013-03-08 2014-03-04 IL-23 kötõ antitestek HUE051357T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361774732P	2013-03-08	2013-03-08

Publications (1)

Publication Number	Publication Date
HUE051357T2 true HUE051357T2 (hu)	2021-03-01

Family

ID=51488096

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HUE14761062A HUE051357T2 (hu)	2013-03-08	2014-03-04	IL-23 kötõ antitestek
HUS2300036C HUS2300036I1 (hu)	2013-03-08	2023-10-18	IL-23 kötõ antitestek

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HUS2300036C HUS2300036I1 (hu)	2013-03-08	2023-10-18	IL-23 kötõ antitestek

Country Status (40)

Country	Link
US (3)	US9023358B2 (hu)
EP (3)	EP2964258B1 (hu)
JP (1)	JP6096938B2 (hu)
KR (2)	KR101775115B1 (hu)
CN (1)	CN105307681B (hu)
AP (1)	AP2015008708A0 (hu)
AR (1)	AR094877A1 (hu)
AU (1)	AU2014226094C1 (hu)
BR (1)	BR112015019611B1 (hu)
CA (1)	CA2901462C (hu)
CL (1)	CL2015002388A1 (hu)
CY (2)	CY1123589T1 (hu)
DK (1)	DK2964258T3 (hu)
EA (1)	EA031524B1 (hu)
EC (1)	ECSP15038626A (hu)
ES (1)	ES2822662T3 (hu)
FI (1)	FIC20230030I1 (hu)
FR (1)	FR23C1036I2 (hu)
HR (1)	HRP20201633T1 (hu)
HU (2)	HUE051357T2 (hu)
IL (2)	IL240731B (hu)
JO (1)	JOP20140049B1 (hu)
LT (2)	LT2964258T (hu)
MA (1)	MA38382A1 (hu)
MX (1)	MX370396B (hu)
MY (1)	MY171226A (hu)
NL (1)	NL301247I2 (hu)
NO (1)	NO2023037I1 (hu)
PE (1)	PE20151529A1 (hu)
PH (1)	PH12015501994B1 (hu)
PL (1)	PL2964258T3 (hu)
PT (1)	PT2964258T (hu)
RS (1)	RS60928B1 (hu)
SG (1)	SG11201507176VA (hu)
SI (1)	SI2964258T1 (hu)
TN (1)	TN2015000348A1 (hu)
TW (1)	TWI636063B (hu)
UA (1)	UA123198C2 (hu)
WO (1)	WO2014137962A1 (hu)
ZA (1)	ZA201505285B (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR102417A1 (es) *	2014-11-05	2017-03-01	Lilly Co Eli	Anticuerpos biespecíficos anti-tnf- / anti-il-23
EP3368066A1 (en) *	2015-10-30	2018-09-05	Eli Lilly and Company	Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof
AR111845A1 (es)	2017-05-03	2019-08-28	Lilly Co Eli	Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos
TWI744617B (zh)	2018-03-30	2021-11-01	美商美國禮來大藥廠	治療潰瘍性結腸炎之方法
TWI808397B (zh)	2018-09-11	2023-07-11	美商美國禮來大藥廠	治療牛皮癬之方法
TWI850365B (zh)	2019-04-22	2024-08-01	美商美國禮來大藥廠	治療克隆氏症(crohn's disease)的方法
CA3154522A1 (en)	2019-10-15	2021-04-22	Christopher Carl Frye	Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CA3164996A1 (en)	2019-12-20	2021-06-14	Novarock Biotherapeutics, Ltd.	Anti-interleukin-23 p19 antibodies and methods of use thereof
CN112807428B (zh) *	2020-06-12	2024-08-27	江苏荃信生物医药股份有限公司	包含抗人白介素23单克隆抗体的药物组合物
WO2022041390A1 (zh) *	2020-08-28	2022-03-03	江苏荃信生物医药股份有限公司	包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法
TW202428304A (zh) *	2020-09-10	2024-07-16	美商美國禮來大藥廠	治療性抗體調配物
EP4347018A1 (en)	2021-05-28	2024-04-10	Eli Lilly and Company	Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis
CN113698480B (zh) *	2021-09-18	2022-07-01	东大生物技术(苏州)有限公司	一组il-23单克隆抗体及其医药用途
EP4409298A1 (en)	2021-09-30	2024-08-07	Eli Lilly and Company	Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
WO2024077113A1 (en) *	2022-10-06	2024-04-11	Eli Lilly And Company	Methods of treating fatigue in ulcerative colitis
AU2024224464A1 (en)	2023-02-22	2025-08-14	Eli Lilly And Company	Regulation of genes in ulcerative colitis and the uses thereof
CN121079321A (zh)	2023-03-10	2025-12-05	伊莱利利公司	治疗溃疡性结肠炎的方法
WO2025083549A1 (en)	2023-10-16	2025-04-24	Sun Pharma Advanced Research Company Limited	Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
US20250228864A1 (en)	2023-11-29	2025-07-17	Gilead Sciences, Inc.	Therapies for the treatment of inflammatory bowel disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6060284A (en)	1997-07-25	2000-05-09	Schering Corporation	DNA encoding interleukin-B30
US7090847B1 (en)	1999-09-09	2006-08-15	Schering Corporation	Mammalian cytokines; related reagents and methods
US7422743B2 (en)	2000-05-10	2008-09-09	Schering Corporation	Mammalian receptor protein DCRS5;methods of treatment
JP4605798B2 (ja)	2003-03-10	2011-01-05	シェーリングコーポレイション	Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
ES2410406T3 (es) *	2005-06-30	2013-07-01	Janssen Biotech, Inc.	Anticuerpos anti-IL-23, composiciones, procedimientos y usos
CN101248088A (zh) *	2005-08-25	2008-08-20	伊莱利利公司	抗il-23抗体
EP1937721B1 (en) *	2005-08-25	2010-07-28	Eli Lilly And Company	Anti-il-23 antibodies
HUE032131T2 (hu) *	2005-08-31	2017-09-28	Merck Sharp & Dohme	Konstruált anti-IL-23 antitestek
EP3219328B1 (en) *	2005-12-29	2020-06-17	Janssen Biotech, Inc.	Human anti-il-23 antibodies, compositions, method and uses
EP2064242A1 (en) *	2007-02-23	2009-06-03	Schering Corporation	Engineered anti-il-23p19 antibodies
ATE554791T1 (de)	2007-02-23	2012-05-15	Schering Corp	Gentechnisch hergestellte anti-il-23p19- antikörper
RS53157B (sr)	2007-03-20	2014-06-30	Eli Lilly And Company	Antitela na sklerostin
JP5290276B2 (ja) *	2007-05-08	2013-09-18	ジェネンテック，インコーポレイテッド	システイン改変抗ｍｕｃ１６抗体および抗体−薬物結合体
WO2009082624A2 (en) *	2007-12-10	2009-07-02	Zymogenetics, Inc.	Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2010142534A1 (en) *	2009-05-27	2010-12-16	Ablynx Nv	Biparatopic protein constructs directed against il-23
EP2635601B1 (en) *	2010-11-04	2016-07-20	Boehringer Ingelheim International GmbH	Anti-il-23 antibodies
US8679767B2 (en)	2011-05-12	2014-03-25	Genentech, Inc.	Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides

2014
- 2014-02-25 TW TW103106335A patent/TWI636063B/zh active
- 2014-02-25 AR ARP140100582A patent/AR094877A1/es active IP Right Grant
- 2014-02-25 JO JOP/2014/0049A patent/JOP20140049B1/ar active
- 2014-03-04 RS RS20201236A patent/RS60928B1/sr unknown
- 2014-03-04 AU AU2014226094A patent/AU2014226094C1/en active Active
- 2014-03-04 US US14/195,889 patent/US9023358B2/en active Active
- 2014-03-04 KR KR1020157024032A patent/KR101775115B1/ko active Active
- 2014-03-04 UA UAA201508670A patent/UA123198C2/uk unknown
- 2014-03-04 JP JP2015561515A patent/JP6096938B2/ja active Active
- 2014-03-04 MX MX2015011959A patent/MX370396B/es active IP Right Grant
- 2014-03-04 HR HRP20201633TT patent/HRP20201633T1/hr unknown
- 2014-03-04 DK DK14761062.0T patent/DK2964258T3/da active
- 2014-03-04 PT PT147610620T patent/PT2964258T/pt unknown
- 2014-03-04 EP EP14761062.0A patent/EP2964258B1/en active Active
- 2014-03-04 CA CA2901462A patent/CA2901462C/en active Active
- 2014-03-04 MA MA38382A patent/MA38382A1/fr unknown
- 2014-03-04 PE PE2015001903A patent/PE20151529A1/es active IP Right Grant
- 2014-03-04 EP EP23207282.7A patent/EP4311558A3/en active Pending
- 2014-03-04 AP AP2015008708A patent/AP2015008708A0/xx unknown
- 2014-03-04 SG SG11201507176VA patent/SG11201507176VA/en unknown
- 2014-03-04 KR KR1020177024414A patent/KR20170103037A/ko not_active Ceased
- 2014-03-04 PL PL14761062T patent/PL2964258T3/pl unknown
- 2014-03-04 ES ES14761062T patent/ES2822662T3/es active Active
- 2014-03-04 PH PH1/2015/501994A patent/PH12015501994B1/en unknown
- 2014-03-04 LT LTEP14761062.0T patent/LT2964258T/lt unknown
- 2014-03-04 EP EP20193400.7A patent/EP3789037A1/en not_active Withdrawn
- 2014-03-04 BR BR112015019611-0A patent/BR112015019611B1/pt active IP Right Grant
- 2014-03-04 CN CN201480012747.7A patent/CN105307681B/zh active Active
- 2014-03-04 HU HUE14761062A patent/HUE051357T2/hu unknown
- 2014-03-04 EA EA201591368A patent/EA031524B1/ru not_active IP Right Cessation
- 2014-03-04 SI SI201431653T patent/SI2964258T1/sl unknown
- 2014-03-04 WO PCT/US2014/020064 patent/WO2014137962A1/en not_active Ceased
- 2014-03-04 MY MYPI2015702927A patent/MY171226A/en unknown
2015
- 2015-05-01 US US14/702,124 patent/US9688753B2/en active Active
- 2015-07-22 ZA ZA2015/05285A patent/ZA201505285B/en unknown
- 2015-08-12 TN TN2015000348A patent/TN2015000348A1/en unknown
- 2015-08-20 IL IL240731A patent/IL240731B/en active IP Right Grant
- 2015-08-26 CL CL2015002388A patent/CL2015002388A1/es unknown
- 2015-09-08 EC ECIEPI201538626A patent/ECSP15038626A/es unknown
2017
- 2017-06-01 US US15/611,008 patent/US20170275356A1/en not_active Abandoned
2020
- 2020-01-14 IL IL272042A patent/IL272042B/en unknown
- 2020-11-16 CY CY20201101081T patent/CY1123589T1/el unknown
2023
- 2023-10-03 FI FIC20230030C patent/FIC20230030I1/fi unknown
- 2023-10-04 NO NO2023037C patent/NO2023037I1/no unknown
- 2023-10-06 CY CY2023021C patent/CY2023021I2/el unknown
- 2023-10-06 NL NL301247C patent/NL301247I2/nl unknown
- 2023-10-13 FR FR23C1036C patent/FR23C1036I2/fr active Active
- 2023-10-18 HU HUS2300036C patent/HUS2300036I1/hu unknown
- 2023-10-23 LT LTPA2023530C patent/LTC2964258I2/lt unknown

Also Published As

Publication number	Publication date
AP2015008708A0 (en)	2015-09-30
PH12015501994B1 (en)	2023-03-01
BR112015019611B1 (pt)	2023-05-02
SG11201507176VA (en)	2015-10-29
AU2014226094B2 (en)	2016-06-23
PE20151529A1 (es)	2015-10-28
KR20150113202A (ko)	2015-10-07
CY2023021I1 (el)	2024-02-16
LTC2964258I2 (hu)	2025-09-10
EP4311558A3 (en)	2024-04-10
EP2964258A1 (en)	2016-01-13
RS60928B1 (sr)	2020-11-30
TW201520225A (zh)	2015-06-01
AU2014226094C1 (en)	2024-10-24
TN2015000348A1 (en)	2017-01-03
FIC20230030I1 (fi)	2023-10-03
LT2964258T (lt)	2020-10-12
IL272042A (en)	2020-02-27
HRP20201633T1 (hr)	2020-12-25
MY171226A (en)	2019-10-03
FR23C1036I1 (fr)	2023-12-08
CA2901462C (en)	2017-07-25
ECSP15038626A (es)	2015-11-30
ES2822662T3 (es)	2021-05-04
EP2964258A4 (en)	2016-10-12
US9688753B2 (en)	2017-06-27
CA2901462A1 (en)	2014-09-12
ZA201505285B (en)	2017-11-29
NL301247I2 (nl)	2023-11-01
SI2964258T1 (sl)	2020-10-30
CY1123589T1 (el)	2022-03-24
US20170275356A1 (en)	2017-09-28
IL240731A0 (en)	2015-10-29
IL272042B (en)	2021-07-29
WO2014137962A1 (en)	2014-09-12
MX2015011959A (es)	2016-04-07
EP3789037A1 (en)	2021-03-10
CN105307681A (zh)	2016-02-03
KR20170103037A (ko)	2017-09-12
CY2023021I2 (el)	2024-09-20
MA38382A1 (fr)	2017-11-30
NO2023037I1 (no)	2023-10-04
EA201591368A1 (ru)	2015-12-30
MX370396B (es)	2019-12-11
DK2964258T3 (da)	2020-09-14
TWI636063B (zh)	2018-09-21
NZ711147A (en)	2021-03-26
PL2964258T3 (pl)	2021-02-08
KR101775115B1 (ko)	2017-09-05
FR23C1036I2 (fr)	2024-10-04
EA031524B1 (ru)	2019-01-31
UA123198C2 (uk)	2021-03-03
US9023358B2 (en)	2015-05-05
CL2015002388A1 (es)	2016-03-04
US20140255422A1 (en)	2014-09-11
JOP20140049B1 (ar)	2021-08-17
NL301247I1 (nl)	2023-10-11
BR112015019611A2 (pt)	2017-08-22
HK1212252A1 (en)	2016-06-10
US20150232552A1 (en)	2015-08-20
JP6096938B2 (ja)	2017-03-15
LTPA2023530I1 (hu)	2023-11-10
HUS2300036I1 (hu)	2024-07-28
JP2016510744A (ja)	2016-04-11
EP2964258B1 (en)	2020-09-02
PT2964258T (pt)	2020-11-06
IL240731B (en)	2020-01-30
AU2014226094A1 (en)	2015-08-27
EP4311558A2 (en)	2024-01-31
PH12015501994A1 (en)	2016-01-11
CN105307681B (zh)	2018-06-26
AR094877A1 (es)	2015-09-02

Publication	Publication Date	Title
CY2023021I1 (el)	2024-02-16	Αντισωματα που δεσμευουν την il-23
IL281485B (en)	2022-02-01	Tracked all-terrain vehicle
IL269528A (en)	2019-11-28	Anti- FCRH5 antibodies
DK2970464T3 (da)	2020-08-03	Anti-lag-3-bindende proteiner
EP3083682C0 (en)	2024-04-17	DOUBLE SPECIFICITY ANTIBODIES
DK3708583T3 (da)	2022-05-16	Ikke-fucosylerede anti-fgfr2iiib-antistoffer
LT3049441T (lt)	2020-02-10	Anti-pdl1 antikūnų kompozicija
DK2951203T3 (da)	2019-08-12	Heterodimere proteiner
GB201322583D0 (en)	2014-02-05	Antibodies
DK3068800T3 (da)	2019-10-21	FcRn-specifikke antistoffer
IL244043A0 (en)	2016-04-21	Antibodies
GB201308658D0 (en)	2013-06-26	Antibodies
GB201315486D0 (en)	2013-10-16	Antibodies
GB201300706D0 (en)	2013-02-27	Antibody
HRP20190085T1 (hr)	2019-03-08	Anti-cd52 protutijela
IL245488B (en)	2020-03-31	Anti- ccl17 antibodies
CL2013003511S1 (es)	2014-08-22	Carpeta
TH1401006962A (th)	2016-06-17	แอนติ-ทรานสกลูตามิเนส 2 แอนติบอดี
GB201318283D0 (en)	2013-11-27	Antibodies